Treatment of pleural mesothelioma: ASCO guideline update Guidelines
| Authors: | Kindler, H. L.; Ismaila, N.; Bazhenova, L.; Chu, Q.; Churpek, J. E.; Dagogo-Jack, I.; Bryan, D. S.; Drazer, M. W.; Forde, P.; Husain, A. N.; Sauter, J. L.; Rusch, V.; Bradbury, P. A.; Cho, B. C. J.; de Perrot, M.; Ghafoor, A.; Graham, D. L.; Khorshid, O.; Lebensohn, A.; White, J.; Hassan, R. |
| Title: | Treatment of pleural mesothelioma: ASCO guideline update |
| Abstract: | ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual. ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines.Clinical Practice Guidelines and other guidance ("Guidance") provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases or stages of diseases. Guidance is based on review and analysis of relevant literature and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and 2 (online only) for more.PURPOSETo provide evidence-based recommendations to practicing physicians and others on the management of pleural mesothelioma (PM).METHODSASCO convened an Expert Panel of medical oncology, thoracic surgery, radiation oncology, pathology, cancer genetics, and advocacy experts to conduct an updated literature search, which included systematic reviews, meta-analyses, randomized controlled trials, and prospective and retrospective comparative observational studies published from 2016 through 2024. Outcomes of interest included survival, disease-free or recurrence-free survival, and quality of life. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations.RESULTSThe literature search identified 110 additional relevant studies to inform the evidence base for this guideline.RECOMMENDATIONSEvidence-based recommendations were developed for surgical cytoreduction, immunotherapy, chemotherapy, pathology, and germline testing in patients with PM.Additional information is available at www.asco.org/thoracic-cancer-guidelines.RECOMMENDATIONSEvidence-based recommendations were developed for surgical cytoreduction, immunotherapy, chemotherapy, pathology, and germline testing in patients with PM.Additional information is available at www.asco.org/thoracic-cancer-guidelines. |
| Keywords: | malignant mesothelioma; extrapleural pneumonectomy; double-blind; phase-iii trial; open-label; american society; brca1-associated protein-1; pemetrexed plus cisplatin; p16 fish; germline bap1 mutations |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 43 |
| Issue: | 8 |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2025-03-10 |
| Language: | English |
| ACCESSION: | WOS:001440602300009 |
| DOI: | 10.1200/jco-24-02425 |
| PROVIDER: | wos |
| PUBMED: | 39778125 |
| Notes: | Article -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work